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In this issue, Bruchas et al. (2011) uncover a novel stress-induced p38aMAPK signaling cascade within sero-
tonergic neurons of the dorsal raphe nucleus that mediates depressive and drug-seeking behaviors. Their
findings have potentially important implications for medication development.Stress plays a prominent role in modern
life. The effects of war, terrorism, political
upheaval, economic uncertainty, climate
change, parental mistreatment, and
bullying can be profoundly stressful.
Emerging evidence from neuroscience
research indicates that stress changes
the brain and that, once established, the
changes can persist for the lifespan. Phar-
macological intervention remains largely
powerless to treat stress-related ill-
nesses, and far too often this lack of
treatment efficacy results in attempts to
self-medicate with alcohol or drugs of
abuse. Without breakthroughs, the
consequences of stressors that occur
today will affect us long into the future.
For these reasons, research that ad-
vances our understanding of the neurobi-
ology of stress is of broad interest. In this
issue of Neuron, Bruchas and colleagues
describe an elegant series of studies
that provides novel insight on the molec-
ular pathways by which stress affects
mood and motivation. The work is partic-
ularly important because it identifies both
familiar and novel targets for medications
that may enable improved treatment—
and perhaps even prevention—of stress-
related illness.
Corticotropin-releasing factor (CRF) is
a peptide that is released in the brain in
response to stress (Koob, 1999). Adminis-
tration of CRF producesmany of the same
physiological and behavioral effects as
stress in people and laboratory animals
(Hauger et al., 2009). Recent evidence
suggests that key stress-related effects
of CRF are mediated by kappa-opioid
receptors (KORs) (Land et al., 2009). The
new work of Bruchas and colleagues
provides exquisite detail on the nature of
this interaction, using an ethologicallyrelevant form of stress (social defeat
stress [SDS]) that recapitulates some of
the physical and psychological conse-
quences that are elements of many
modern-day stressors and is known to
cause persistent behavioral and molec-
ular adaptations in mice (Krishnan et al.,
2007). Focusing on the dorsal raphe
nucleus (DRN), a brain region in which
CRF, KOR, and serotonin (5-HT) systems
converge, the authors show that SDS
causes an increase in the activity (phos-
phorylation) of the intracellular signaling
molecule p38a MAPK. This effect is
mimicked by administration of a highly
selective KOR agonist (U50,488) and
blocked by a highly selective KOR an-
tagonist (norBNI), demonstrating depen-
dence on KOR function. Using viral-
mediated gene transfer and genetic
engineering, they demonstrate that p38a
MAPK activation within the DRN is
responsible for the ability of stress to
trigger depressive- and anxiety-like
states, including dysphoria (aversion)
and drug-seeking behavior. Since p38a
MAPK is expressed ubiquitously, they
used selective promoters to further isolate
these effects to 5-HT-containing neurons.
Importantly, they then used neurochem-
istry and immunoblotting techniques to
demonstrate that p38a MAPK activation
causes translocation of the serotonin
transporter (SERT) from intracellular
stores to neuronal membranes, thereby
increasing clearance of extracellular
5-HT (Figure 1). These data raise the
possibility that the therapeutic effects of
selective serotonin reuptake inhibitors
(SSRIs) could be related, at least in part,
to an ability to offset stress-induced
enhancements of SERT function within
the DRN.Neuron 71The work of Bruchas and colleagues
has important implications for medication
development because it highlights the fact
that there are numerous pathways that
converge on common cell functions. As
one example, SSRIs andKORantagonism
may produce functionally comparable
effects on 5-HT activity within the DRN,
though via differentmechanisms (i.e., inhi-
bition of SERT versus reduced membrane
insertion of SERT). This diversity should
enable the selection of new drug candi-
dates that have fewer off-target effects
andgreater safety. The hypothetical ability
of SSRIs to correct a stress-induced dys-
regulation of 5-HT function within the DRN
provides a rationale for retaining this
mechanism in future antidepressant
medications, including those that simulta-
neously block the reuptake of othermono-
amines (e.g., norepinephrine, dopamine).
The work also strengthens emerging
evidence that KOR antagonists might be
useful for not only treating but also pre-
venting stress-related illness (Land et al.,
2009; Carlezon et al., 2009), particularly
when exposure to stressful events can
be anticipated in advance. Finally, it
has exciting (albeit still theoretical) impli-
cations for the development of safer
medications for pain. There was once
considerable interest in developing KOR
agonists as nonaddictive analgesic drugs:
stimulation of KORs produces analgesia
(Pasternak, 1980), while the lack of mu-
opioid receptor (MOR) activation mini-
mizes abuse liability. Unfortunately, early
clinical studies indicated that KOR
agonists produced a variety of effects,
including dysphoria and psychotomime-
sis (Pfeiffer et al., 1986), which made
them intolerable and thus poor candidates
for medication development. The data of, August 11, 2011 ª2011 Elsevier Inc. 383
Figure 1. Hypothetical Cascade by which Stress Produces
Depressive Effects via Processes in the Dorsal Raphe Nucleus
Stressors such as social defeat stress (SDS) cause release of corticotropin-
releasing factor (CRF), which in turn activates dynorphin-containing inputs to
the dorsal raphe nucleus (DRN). Dynorphin stimulation of kappa-opioid recep-
tors (KORs) activates (phosphorylates [P]) p38a MAPK, a crucial mediator of
dysphoric (aversive) states. One downstream consequence of p38a MAPK
is translocation of SERT to neuronal membranes, which decreases extracel-
lular concentrations of serotonin (5-HT) and alters stimulation of serotonin
receptors (5HTRs). This hyposerotonergic state likely affects output to the
prefrontal cortex (PFC), an element of mesocorticolimbic circuits implicated
in motivation and emotion. Based on Bruchas et al., 2011, Meloni et al.,
2008, and Carlezon and Thomas, 2009.
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suggests that loss of p38a
MAPK function does not alter
pain sensitivity or the ability
of stress-induced KOR acti-
vation to produce analgesia.
As such, it may be possible
to design KOR agonists that
do not activate p38a MAPK
using concepts such as li-
gand-directed signaling (also
called biased agonism or
functional selectivity), a pro-
cess by which a drug can
simultaneously act as an
agonist and an antagonist at
different functions mediated
by the same receptor (Urban
et al., 2007; Bruchas and
Chavkin, 2010). Thediscovery
of such drugs would be facili-
tated by the availability of
large chemical libraries and
the development of high-
throughput screening proce-
dures that identify com-
pounds that activate KORs
but not p38a MAPK. Obvi-
ously, it would be important
to confirm that compounds
that activate KORs but not
p38a MAPK are motivation-
ally neutral and do not replace
the dysphoric effects of KOR
agonists with the euphoric
effects of MOR agonists.Several important questions remain.
Although the finding that stress increases
SERT functionwithin theDRNstrengthens
long-hypothesized links among stress,
5-HT, and the therapeutic effects of
SSRIs, it is well established that acute
decreases in 5-HT alone are not sufficient
to produce depression in normal humans
(Heninger et al., 1996). Furthermore, it is
still unclear why SSRIs and other antide-
pressant medications require chronic (on
the scale of weeks) administration before
they relieve the symptoms of depressive
and anxiety disorders. Rapid effects in
animal models might occur simply
because the interventions are given
sooner—often immediately before or after
a normal (‘‘nondepressed’’) animal is
exposed to stress—than they are given
in humans, thereby arresting stress-
induced neuroadaptations before they
are established. However, the time lag is384 Neuron 71, August 11, 2011 ª2011 Elsevoften interpreted as meaning that antide-
pressants need to produce secondary
neuroadaptations before they become
effective (Duman and Monteggia, 2006).
It is conceivable that such neuroadapta-
tions include SSRI-induced downregula-
tion in the function of certain 5-HT
receptor subtypes and increases in neuro-
trophin expression; at least on the surface,
thesepossibilities are not easily integrated
into the current DRN-related model pro-
posed by Bruchas and colleagues, nor is
the observation that acute administration
of SSRIs can exacerbate anxiety in certain
models (Carlezon et al., 2009). Another
issue to be resolved is whether the
dysphoric consequences of stress are
mediated solely within the DRN, or if they
are dependent upon interactions with
other brain circuits. As one example, it is
known that stress can change the activity
of DRN outputs to the prefrontal cortexier Inc.(PFC) (Meloni et al., 2008).
These changes, in turn, may
affect the activity of the me-
socorticolimbic system and
its outputs (e.g., amygdala),
brain areas more classically
implicated in motivation and
emotion, as well as key
behavioral effects of KOR
agonists and antagonists
(Carlezon and Thomas, 2009,
Knoll et al., 2011). Regard-
less, this newwork delineates
a molecular cascade that
underlies stress vulnerability
and resilience and can be ex-
ploited for the rational design
and development of new
treatments for stress-related
psychiatric disorders and
chronic pain.
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The synaptic basis underlying food intake is poorly understood. New research shows that an animal’s satiety
state dictates the polarity of long-term inhibitory synaptic plasticity in the hypothalamus, which is mediated
by an activity-dependent competition between endocannabinoid and nitric oxide signaling.As the homeostatic hub in the central
nervous system, the hypothalamus or-
chestrates an enormous array of neuroen-
docrine and behavioral processes such
as growth, reproduction, stress, and, rele-
vant to the topic at hand, food intake. How
are satiety-related signals integrated at
the cellular and system level to give a
reliable and appropriate behavioral re-
sponse? In this issue of Neuron, new
research by Crosby et al. (2011) brings
us one step closer to answering this
important question by improving our
understanding of the molecular underpin-
nings and experience-dependent cues
that drive synaptic plasticity in the
hypothalamus.
The hypothalamus is comprised of
numerous anatomically and functionally
distinct nuclei. One of these nuclei, the
dorsomedial nucleus of the hypothalamus
(DMH), is important because it controls
heart rate, blood pressure, and body
temperature (Ulrich-Lai and Herman,
2009). Considerable lesioning data impli-
cate the DMH in feeding (Bellinger and
Bernardis, 2002). When ablated, animals
become hypophagic. Food-seeking
behavior is also regulated by other hypo-
thalamic nuclei, such as the lateral hypo-
thalamic area and ventromedial hypotha-
lamic nucleus. The DMH receives myriadexcitatory, inhibitory, and neuromodula-
tory afferents from brain regions including
other hypothalamic nuclei and higher
cortical and limbic regions as well as the
brain stem (Berthoud, 2002).
One attractive aspect, or perhaps
shortcoming, of hypothalamic synaptic
physiology is that so much of it remains
unexplored. Enter Crosby et al. (2011) to
take a stab. They focused on two features
of the DMH: (1) how afferent activity
modifies synaptic transmission within
this nucleus; and (2) how food-deprivation
instructs experience-dependent signaling
at DMH synapses. To address these
issues, the authors performed in vitro
whole-cell patch clamp recordings in
rodent brain slices containing the DMH.
In response to high-frequency stimulation
(HFS) of presynaptic fibers, amanipulation
that recruits both glutamatergic and
GABAergic inputs, they found a robust
form of long-term depression of inhibitory
synapses, here referred to as i-LTD for
consistency with other forms of inhibitory
synaptic plasticity previously reported
(Castillo et al., 2011; Woodin and Maffei,
2011). In line with i-LTD observed in other
brain areas (Heifets and Castillo, 2009),
Crosby et al. (2011) found that i-LTD in
the DMH requires endogenous cannabi-
noid (eCB) signaling. eCBs are lipid-derived messengers synthesized in an
activity-dependent manner from post-
synaptic compartments in response to
metabotropic receptor activation and/or
increased intracellular Ca2+ rise. Typi-
cally, once mobilized, they retrogradely
depress neurotransmitter release by vir-
tue of type-1 cannabinoid (CB1)-receptor
activation (Kano et al., 2009). Intriguingly,
unlike eCB-mediated i-LTD at other
central synapses, i-LTD in the DMH was
not associated with significant changes
in the paired-pulse ratio (PPR) and/or the
coefficient of variation (CV), two parame-
ters classically used to determine whether
a form of plasticity is expressed pre- or
postsynaptically. As a result, it is unclear
if this form of plasticity is expressed pre-
or postsynaptically.
Unexpectedly, when the authors
blocked CB1 receptors pharmacologi-
cally or used CB1 receptor knockout
mice, they observed a switch in the
polarity of GABAergic synaptic transmis-
sion, revealing long-term potentiation
(i-LTP) whose expression is likely presyn-
aptic as indicated by a decrease in PPR
and CV. As for the i-LTP reported in the
ventral tegmental area (Nugent et al.,
2007), Crosby et al. (2011) found that
induction of i-LTP in the DMH requires
nitric oxide (NO) signaling. NO is a highly, August 11, 2011 ª2011 Elsevier Inc. 385
